drugset
drugset / Trial / NCT03633448

Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents

NCT03633448 ↗

Phase 1 Completed 24 enrolled Reckitt Benckiser Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

Evaluate the pharmacokinetics (PK), Safety and tolerability of guaifenesin (Mucinex®) in an immediate-release formulation when a single dose is administered in adolescents and in adults when compared to Children.

Timeline

Start
2011-06-18
Primary completion
2011-07-01
Completion
2011-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Guaifenesin Small molecule 200 mg —
Subject Guaifenesin Small molecule 400 mg —

Indications

No indication recorded.